Literature DB >> 24511481

Formulation, evaluation and optimization of pectin- bora rice beads for colon targeted drug delivery system.

Kuldeep Hemraj Ramteke1, Lilakant Nath2.   

Abstract

PURPOSE: The purpose of this research was to established new polysaccharide for the colon targeted drug delivery system, its formulation and in vitro and in vivo evaluation.
METHODS: Microspheres containing pectin and bora rice were prepared by ionotropic gelation technique using zinc acetate as cross linking agent and model drug used was glipizide. A 3(2) full factorial design was employed to study the effect of independent variables, polymer to drug ratio (A), and concentration of cross linking agent (B) on dependent variables, particle size, swelling index, drug entrapment efficiency and percentage drug release.
RESULTS: RESULTS of trial batches indicated that polymer to drug ratio and concentration of cross linking agent affects characteristics of beads. Beads were discrete, spherical and free flowing. Beads exhibited small particle size and showed higher percentage of drug entrapment efficiency. The optimized batch P2 exhibited satisfactory drug entrapment efficiency 68% and drug release was also controlled for more than 24 hours. The polymer to drug ratio had a more significant effect on the dependent variables. In vivo gamma scintigraphy study of optimized pectin-bora rice beads demonstrated degradation of beads whenever they reached to the colon.
CONCLUSION: Bora rice is potential polysaccharide for colon targeted drug delivery system.

Entities:  

Keywords:  Bora Rice; Factorial design; Glipizide; In Vivo study; Pectin

Year:  2013        PMID: 24511481      PMCID: PMC3915817          DOI: 10.5681/apb.2014.025

Source DB:  PubMed          Journal:  Adv Pharm Bull        ISSN: 2228-5881


  11 in total

1.  Delivery of glipizide from asymmetric membrane capsules using encapsulated excipients.

Authors:  A G Thombre; A R DeNoto; D C Gibbes
Journal:  J Control Release       Date:  1999-08-05       Impact factor: 9.776

Review 2.  Colon-specific drug delivery: new approaches and in vitro/in vivo evaluation.

Authors:  Libo Yang; James S Chu; Joseph A Fix
Journal:  Int J Pharm       Date:  2002-03-20       Impact factor: 5.875

Review 3.  Pectin-based systems for colon-specific drug delivery via oral route.

Authors:  LinShu Liu; Marshall L Fishman; Joseph Kost; Kevin B Hicks
Journal:  Biomaterials       Date:  2003-08       Impact factor: 12.479

4.  Preparation and characteristics of high-amylose corn starch/pectin blend microparticles: a technical note.

Authors:  Kashappa Goud H Desai
Journal:  AAPS PharmSciTech       Date:  2005-09-30       Impact factor: 3.246

5.  Colonic drug delivery: influence of cross-linking agent on pectin beads properties and role of the shell capsule type.

Authors:  G Dupuis; O Chambin; C Génelot; D Champion; Y Pourcelot
Journal:  Drug Dev Ind Pharm       Date:  2006-08       Impact factor: 3.225

Review 6.  Polysaccharides in colon-specific drug delivery.

Authors:  V R Sinha; R Kumria
Journal:  Int J Pharm       Date:  2001-08-14       Impact factor: 5.875

7.  Oral delayed-release system based on Zn-pectinate gel (ZPG) microparticles as an alternative carrier to calcium pectinate beads for colonic drug delivery.

Authors:  Ibrahim El-Gibaly
Journal:  Int J Pharm       Date:  2002-01-31       Impact factor: 5.875

8.  Eudragit-coated pectin microspheres of 5-fluorouracil for colon targeting.

Authors:  Amol Paharia; Awesh K Yadav; Gopal Rai; Sunil K Jain; Shyam S Pancholi; Govind P Agrawal
Journal:  AAPS PharmSciTech       Date:  2007-02-16       Impact factor: 3.246

Review 9.  Glipizide. A review of the pharmacoeconomic implications of the extended-release formulation in type 2 diabetes mellitus.

Authors:  R H Foster; G L Plosker
Journal:  Pharmacoeconomics       Date:  2000-09       Impact factor: 4.981

10.  Pectin-based microspheres for colon-specific delivery of vancomycin.

Authors:  Federica Bigucci; Barbara Luppi; Libera Monaco; Teresa Cerchiara; Vittorio Zecchi
Journal:  J Pharm Pharmacol       Date:  2009-01       Impact factor: 3.765

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.